Seattle Genetics, Inc. SGEN today presented preclinical data from
SGN-CD33A, an antibody-drug conjugate (ADC) in development for the treatment
of acute myeloid leukemia (AML), at the 54^th American Society of Hematology
(ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta,
GA. SGN-CD33A is a novel CD33-directed ADC utilizing Seattle Genetics' next
generation technology. The CD33 antibody is attached to a highly potent
cytotoxic agent called a pyrrolobenzodiazepine (PBD) dimer via a proprietary
site-specific conjugate technology to a monoclonal antibody with engineered
cysteines (EC-mAb). Seattle Genetics expects to advance SGN-CD33A into a phase
I clinical trial in 2013.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in